This is not the most recent version of the article. View current version (30 SEP 2014)

Intervention Protocol

You have free access to this content

Azapirones versus placebo for panic disorder in adults

  1. Giuseppe Guaiana1,*,
  2. Corrado Barbui2,
  3. Debbie Chiodo3,
  4. Andrea Cipriani4,
  5. Simon JC Davies5,
  6. Hissei Imai6,
  7. Markus Koesters7

Editorial Group: Cochrane Depression, Anxiety and Neurosis Group

Published Online: 26 NOV 2013

DOI: 10.1002/14651858.CD010828


How to Cite

Guaiana G, Barbui C, Chiodo D, Cipriani A, Davies SJC, Imai H, Koesters M. Azapirones versus placebo for panic disorder in adults (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 11. Art. No.: CD010828. DOI: 10.1002/14651858.CD010828.

Author Information

  1. 1

    Western University, Department of Psychiatry, St Thomas, Ontario, Canada

  2. 2

    University of Verona, Department of Public Health and Community Medicine, Section of Psychiatry, Verona, Italy

  3. 3

    Centre for Addiction and Mental Health, Social and Epidemiological Research Department, London, Ontario, Canada

  4. 4

    University of Oxford, Department of Psychiatry, Oxford, UK

  5. 5

    University of Bristol, School of Social and Community Medicine, Bristol, UK

  6. 6

    Kyoto University Graduate School of Medicine / School of Public Health, Department of Field Medicine, Kyoto, Japan

  7. 7

    Ulm University, Department of Psychiatry ll, Guenzburg, Germany

*Giuseppe Guaiana, Department of Psychiatry, Western University, Saint Thomas Elgin General Hospital, 189 Elm Street, St Thomas, Ontario, N5R 5C4, Canada. Giuseppe.Guaiana@sjhc.london.on.ca. gguaiana@stegh.on.ca.

Publication History

  1. Publication Status: New
  2. Published Online: 26 NOV 2013

SEARCH

This is not the most recent version of the article. View current version (30 SEP 2014)

 

Background

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Contributions of authors
  7. Declarations of interest
  8. Sources of support
  9. Notes
 

Description of the condition

A panic attack is a discrete period of fear or anxiety that has a rapid onset and reaches a peak within 10 minutes, during which at least four of 13 characteristic symptoms are experienced. Many of these symptoms involve bodily systems, such as racing heart, chest pain, sweating, shaking, dizziness, flushing, stomach churning, faintness and breathlessness. Further recognised panic attack symptoms involve fearful cognitions, such as fears of collapse, going mad or dying and derealization (APA 1994).

Panic disorder first entered diagnostic classification systems in 1980 with the publication of the Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition (DSM-III), after it was observed that patients with panic attacks responded to treatment with the tricyclic antidepressant (TCA) imipramine (Klein 1964). For a diagnosis of panic disorder, further conditions must be met related to the frequency of attacks, the need for some attacks to come on ‘out of the blue’ rather than in a predictable externally triggered situation and exclusions wherein attacks are attributable solely to medical causes or panic-inducing substances, notably caffeine. DSM-IV requires additionally that at least one attack has been followed by (a) persistent concern about having additional attacks, (b) worry about the implications of the attack or its consequences or (c) a significant change in behaviour related to the attacks (APA 1994).

Panic disorder is common in the general population, with a lifetime prevalence of 1% to 4% (Eaton 1994; Bijl 1998). In primary care settings, panic syndromes have been reported to have a prevalence of around 10% (King 2008). The origin of panic disorder is not fully understood and is probably heterogeneous. Biological theories incorporate faulty triggering of a built-in anxiety response, possibly a suffocation alarm. Evidence for this comes from biological challenge tests (lactate and carbon dioxide trigger panic in those with the disorder) and from animal experiments and neuroimaging studies in humans that show activation of fear circuits, such as that involving the periaqueductal grey matter (Gorman 2000).

Agoraphobia is anxiety about being in places or situations from which escape might be difficult or embarrassing, or in which help may not be available, in the event of a panic attack (APA 1994). Agoraphobia can occur with panic disorder (APA 1994). About one-fourth of people suffering from panic disorder also have agoraphobia (Kessler 2006). The presence of agoraphobia is associated with increased severity and worse outcome (Kessler 2006). Several risk factors predict the development of agoraphobia in people suffering from panic disorder: female gender, more severe dizziness during panic attacks, cognitive factors, dependent personality traits and social anxiety disorder (Starcevic 2009).

Panic disorder, with or without agoraphobia, is highly comorbid with other psychiatric disorders, such as drug dependence, major depression, bipolar I disorder, social phobia, specific phobia and generalised anxiety disorder (Grant 2006). It is estimated that generalised anxiety disorder co-occurs in 68% of people with panic disorder, whilst major depression has a prevalence of 24% to 88% among people with panic disorder (Starcevic 2009).

 

Description of the intervention

Treatment of panic disorder includes psychological and pharmacological interventions, often used in combination (Watanabe 2009). Historically, pharmacological interventions for panic disorder have been based on the use of monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs) (Bruce 2003; Stein 2010; Batelaan 2011). However, MAOIs and TCAs are burdened by severe adverse effects, such as dietary restrictions (to avoid hypertensive crisis) for MAOIs and anticholinergic, arrhythmogenic and overall poor tolerability for TCAs (Wade 1999). Benzodiazepines (BDZs), particularly high-potency ones, have been used as an alternative to MAOIs and TCAs in panic disorder (Stein 2010). Recent guidelines (British Association for Psychopharmacology (BAP) guideline: BAP 2005; American Psychiatric Association (APA) guideline: APA 2009; National Institute for Health and Care Excellence (NICE) guideline: NICE 2011) consider antidepressants, mainly selective serotonin reuptake inhibitors (SSRIs), as first-line pharmacological treatment for panic disorder because of their more favourable adverse effect profile over MAOIs and TCAs. Azapirones are a class of drugs used as anxiolytics. They seem to be associated with less drowsiness, psychomotor impairment, alcohol potentiation and potential for addiction or abuse than BDZs (Napoliello 1991). Examples include alnespirone, binospirone, buspirone, enilospirone, eptapirone, gepirone, ipsapirone, revospirone, tandospirone and zalospirone, all of which are serotonin 1A (5-HT1A) receptor partial agonists. Other properties include 5-HT2A and α1- and α2-adrenergic receptor antagonism, which differ between individual drugs (Kishi 2013).

 

How the intervention might work

The exact mechanism of action of azapirones in anxiety disorders has not been established, but they are known to be partial agonists at the serotonin 5-HT1A receptor. In some brain areas such as the raphe nuclei, this is an autoreceptor that when fully activated may act in a homeostatic capacity, exerting an inhibitory effect to oppose the otherwise beneficial effects of increasing serotonin availability.

Evidence suggests that under-activity of 5-HT1A receptors is associated with anxiety. In animal studies, knockout mice lacking the 5-HT1A receptor in the cortex and limbic system show more anxiety behaviours than those who have the receptor intact (Parks 1998). In humans, 5-HT1A receptor binding availability in the brain correlates inversely with anxiety in normal volunteers (Tauscher 2001). In adults with untreated panic disorder, evidence derived from positron emission tomography (PET) studies shows 5-HT1A receptor abnormalities in specific brain regions (Nash 2008), with lower 5-HT1A receptor availability in the raphe and amygdala, which are implicated in anxiety, as well as in the anterior medial and lateral temporal lobes and the orbitofrontal cortex. It is conceivable therefore that as partial agonists, azapirones may generate sufficient 5-HT1A receptor activation in key brain areas to counteract anxiety, but not to the extent that inhibitory homeostatic autoreceptor processes are invoked, as would be the case if only serotonin were binding to the receptor unopposed. Over longer treatment periods, azapirones can downregulate 5-HT1A receptor numbers, which may contribute to the anxiolytic effect by removing the potential for unhelpful homeostatic effects by activated 5-HT1A receptors. The 5-HT1A responsivity by ipsapirone, one of the azapirones, was shown to be different in trial participants with panic disorder (Lesch 1992; Brooks 2002), so that 5-HT1A receptor–related serotonergic dysfunction is said to be linked to the pathophysiology of panic disorder (Lesch 1992).

Recent evidence has suggested an alternative mechanism of action for azapirones based on the dopamine system. Buspirone is an antagonist at nigrostriatal dopamine D2 and D3 receptors. In vitro data indicate that affinity for D3 is considerably greater than that for D2 and is slightly greater than that for 5-HT1A receptors. Evidence from animal studies shows that dopamine D3 receptor function may have an effect on anxiety behaviours (Diaz 2011). Although the dopaminergic theory of azapirone action remains unproven, evidence in humans is emerging to confirm that standard therapeutic doses of azapirones such as buspirone can achieve significant D3 receptor occupancy (Payer 2013).

Finally, azapirone inhibition of α2-adrenoceptors on serotonergic neurons may also play a role in the anxiolytic effects of buspirone. As these receptors moderate serotonin release, azapirone may be instrumental in increasing overall serotonin availability through this mechanism.

 

Why it is important to do this review

Azapirones are not widely used in panic disorder. Evidence for their efficacy in panic disorder is unclear. To our knowledge, no systematic study on azapirones in panic disorder has been recently conducted. It would be important to understand how treatment can assist in recovery from panic disorder and what agents are most effective in the treatment of panic. A review is needed to help prescribers identify the effect size of active treatment compared with placebo in treating panic disorder, so they can be better guided in selecting the most appropriate pharmacological agent. Another two Cochrane reviews on antidepressants versus placebo in panic disorder and benzodiazepines versus placebo in panic disorder are in progress; findings reported in these reviews will further help clinicians in identifying effective pharmacological treatments for panic disorder (Guaiana 2013; Guaiana 2013a). This review will add to the Cochrane reviews on combination therapy for panic disorder (specifically, psychotherapy plus benzodiazepines (Watanabe 2009) and psychological therapies for panic disorder (Pompoli 2013)).

 

Objectives

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Contributions of authors
  7. Declarations of interest
  8. Sources of support
  9. Notes

To assess the effects of azapirones on panic disorder in adults, specifically:

  1. to determine the efficacy of azapirones in alleviating symptoms of panic disorder, with or without agoraphobia, in comparison with placebo;
  2. to review the acceptability of azapirones in panic disorder, with or without agoraphobia, in comparison with placebo; and
  3. to investigate the adverse effects of azapirones in panic disorder with or without agoraphobia, including general prevalence of adverse effects, compared with placebo.

 

Methods

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Contributions of authors
  7. Declarations of interest
  8. Sources of support
  9. Notes
 

Criteria for considering studies for this review

 

Types of studies

Randomised, double-blind, controlled trials using a parallel-group design that compare azapirones with placebo as monotherapy.

We will include cross-over trials, randomised placebo-controlled trials with more than two arms and cluster-randomised placebo-controlled trials.

We will exclude quasi-randomised trials, such as those in which allocation is performed by using alternate days of the week.

 

Types of participants

Participants 18 years of age or older with a primary diagnosis of panic disorder, with or without agoraphobia, diagnosed according to any of the following criteria: Feighner criteria, Research Diagnostic Criteria, DSM-III, DSM-III-R, DSM-IV or International Classification of Diseases, 10th Edition (ICD-10). In case study eligibility focused on agoraphobia, rather than panic disorder, studies are included if operationally diagnosed according to the above-named criteria, and when it can be safely assumed that at least 30% of participants were suffering from panic disorder as defined by the above criteria. Evidence suggests that more than 95% of participants with agoraphobia seen clinically suffer from panic disorder as well (Goisman 1995). However, the effect of the inclusion of these studies will be examined in a sensitivity analysis.

We will exclude participants with serious comorbid physical disorders (e.g. myocardial infarction, chronic obstructive pulmonary disorder, uncontrolled diabetes, electrolyte disturbances), as they may confound treatment effectiveness and tolerability.

We will include participants with comorbid mental disorders, but the effect of including these participants will be examined in sensitivity analyses.

 

Types of interventions

Any trial comparing azapirones (buspirone, gepirone, tandospirone, ipsapirone or lesopitron) as monotherapy with placebo in the treatment of panic disorder, with or without agoraphobia. Only acute treatment studies treating participants for less than six months will be included. Relapse prevention studies will be excluded.

No restriction on dose, frequency, intensity, route of administration or duration will be applied.

Studies administering psychosocial therapies targeted at panic disorder concurrently will also be excluded.

 

Types of outcome measures

 

Primary outcomes

1. Rate of 'response' (i.e. substantial improvement from baseline as defined by the original investigators). Examples include “very much or much improved” according to the Clinical Global Impression Change Scale, more than 40% reduction on the Panic Disorder Severity Scale and more than 50% reduction on the Fear Questionnaire Agoraphobia Subscale.

2. Total number of dropouts for any reason as a proxy measure of treatment acceptability.

 

Secondary outcomes

3. 'Remission' (i.e. satisfactory end-state as defined by global judgement of the original investigators). Examples include “panic free” and “no or minimal symptom” according to the Clinical Global Impression Severity Scale.

4. Panic symptom scales and global judgement on a continuous scale. Examples include Panic Disorder Severity Scale total score (0 to 28), Clinical Global Impression Severity Scale (1 to 7), Clinical Global Impression Change Scale (1 to 7), etc. When multiple measures were used, steps will be followed in the order as above, with preference given to panic symptoms scales. The actual measure entered into meta-analysis will be indicated at the top of the listings in the 'Table of included studies'.

5. Frequency of panic attacks, as recorded, for example, by a panic diary.

6. Agoraphobia, as measured, for example, by Fear Questionnaire, Mobility Inventory, behavioural avoidance test, etc.

7. General anxiety, as measured, for example, by Hamilton Rating Scale for Anxiety, Beck Anxiety Inventory, State-Trait Anxiety Index, Sheehan Patient-Rated Anxiety Scale, Anxiety Subscale of Symptom Checklist (SCL)-90-R, etc.

8. Depression, as measured, for example, by Hamilton Rating Scale for Depression, Beck Depression Inventory, Depression Subscale of SCL-90-R, etc.

9. Social functioning, as measured, for example, by Sheehan Disability Scale, Global Assessment Scale, Social Adjustment Scale-Self Report, etc.

10.Quality of life, as measured, for example, by Short Form (SF)-36, SF-12, etc.

11. Patient satisfaction with treatment.

12. Economic costs.

13. Number of dropouts due to adverse effects.

14. Number of participants experiencing at least one adverse effect.

 

Timing of outcome assessment

All outcomes are short-term, which we define as acute phase treatment that normally would last two to six months.

When studies report response rates at different time points within two to six months, the time point closest to 12 weeks will be given preference.

 

Search methods for identification of studies

 

Electronic searches

 

The Cochrane Depression, Anxiety and Neurosis Review Group's Specialised Register (CCDANCTR)

The Cochrane Depression, Anxiety and Neurosis Group (CCDAN) maintains two clinical trials registers at its editorial base in Bristol, UK: a references register and a studies based register. The CCDANCTR-References Register contains over 31,500 reports of RCTs in depression, anxiety and neurosis. Approximately 65% of these references have been tagged to individual, coded trials. The coded trials are held in the CCDANCTR-Studies Register and records are linked between the two registers through the use of unique Study ID tags. Coding of trials is based on the EU-Psi coding manual, using a controlled vocabulary, please contact the CCDAN Trials Search Coordinator for further details. Reports of trials for inclusion in the Group's registers are collated from routine (weekly), generic searches of MEDLINE (1950-), EMBASE (1974-) and PsycINFO (1967-); quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL) and review specific searches of additional databases. Reports of trials are also sourced from international trials registers c/o the World Health Organization's trials portal (the International Clinical Trials Registry Platform (ICTRP)), pharmaceutical companies, the handsearching of key journals, conference proceedings and other (non-Cochrane) systematic reviews and meta-analyses.

Details of CCDAN's generic search strategies can be found on the Group's website.

The CCDAN registers will be searched using the following terms.

 
Search 1: Azapirones and Panic
 
CCDANCTR-Studies

Diagnosis = (panic) and Intervention = ((azapirone or alnespirone or binospirone or buspirone or enilospirone or eptapirone or gepirone or ipsapirone or revospirone or tandospirone or zalospirone or *piron*) and placebo*)

 
CCDANCTR-References

The References Register will be searched using the following free-text terms to identify additional untagged references:
(panic or agoraphobi*) and (azapirone or alnespirone or binospirone or buspirone or enilospirone or eptapirone or gepirone or ipsapirone or revospirone or tandospirone or zalospirone or *piron*)

Abstracts will be screened for azapirone trials and full-text articles will be retrieved, where necessary, to check for placebo controls.

 
Search 2: Azapirones and Anxiety Disorders not otherwise specified (ADNOS)

A further search of the CCDANCTR will be carried out to identify reports of azapirone trials for ‘Anxiety Disorders Not Otherwise Specified’ (ADNOS).

 
CCDANCTR-Studies

Condition = (anxiety or anxious) and Intervention = ((azapirone or alnespirone or binospirone or buspirone or enilospirone or eptapirone or gepirone or ipsapirone or revospirone or tandospirone or zalospirone or *piron*) and placebo*)

 
CCDANCTR- References

The References Register will be searched using the following free-text terms to identify additional untagged references: ((anxiety or anxious or ADNOS) and (azapirone or alnespirone or binospirone or buspirone or enilospirone or eptapirone or gepirone or ipsapirone or revospirone or tandospirone or zalospirone or *piron*)) and not (agoraphobi* or panic or (social NEAR (anxi* or phobi*)) or generalised or generalized or obsessive or compulsive or OCD or PTSD or post-trauma* or “post trauma*” or posttrauma*)

Abstracts will be screened and full-text articles will be retrieved, where necessary, to check for appropriate placebo controlled trials.

No restrictions will be placed on date, language or publication status.

National and International Trials Registers

Complementary searches will be conducted on the WHO International Clinical Trials Registry Platform (ICTRP) and ClinicalTrials.gov.

 

Searching other resources

Reference lists of all included studies, non-Cochrane systematic reviews and major textbooks of affective disorders (written in English) will be checked by review authors, for published reports and citations of unpublished research. A citation search will also be conduct via the Web of Science (included studies only) to identify additional works. Experts in the field will be contacted.

 

Data collection and analysis

 

Selection of studies

The selection of trials for inclusion in this systematic review will be done independently by two of the authors: GG (clinical expertise) and MK (methodological expertise).

GG and MK will inspect the search hits by reading the titles and the abstracts to see whether they meet the criteria. Possible doubts will be resolved by consultation with the co–review authors. Each potentially relevant study located in the search will be obtained as a full article and independently assessed for inclusion by two review authors, and, in the case of discordance, resolution will be sought by discussion between the review authors. The discordance in the selection of studies will be calculated using Cohen’s kappa (k) (Cohen 1960), a more robust measure than a simple per cent agreement calculation because it takes into account the agreement between review authors that occurs by chance. When it will not be possible to evaluate the study because of language problems or missing information, the study will be classified as 'study awaiting assessment' until a translation or further information can be obtained. Reasons for the exclusions of trials will be reported in the 'Characteristics of excluded studies' table.

All decisions made during the selection process, along with numbers of studies and references, will be recorded and presented in a PRISMA flow diagram (Moher 2009) at the end of the review.

 

Data extraction and management

Two review authors will use a data extraction form to independently extract the data from included studies concerning participant characteristics (age, sex, severity of panic disorder, study setting), intervention details (dosage, duration of study, sponsorship), study characteristics (blinding, allocation, etc.) and outcome measures of interest. The extraction sheet will be piloted by a sample of 10% of the included studies. Again, any disagreement will be resolved by consensus or by the third member of the review team. If necessary, authors of studies will be contacted to obtain clarification.

 

Main comparison

  1. Azapirones as a whole versus placebo.

 

Assessment of risk of bias in included studies

Two review authors will independently assess risk of bias using the tool described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). This tool encourages consideration of how the sequence was generated, how allocation was concealed, the integrity of blinding at outcome assessment, the completeness of outcome data, selective reporting and other biases. Sponsorship bias will also be considered.

The risk of bias, in each domain and overall, is assessed and categorised as:

  1. low risk of bias: plausible bias unlikely to seriously alter the results;
  2. high risk of bias: plausible bias that seriously weakens confidence in the results; or
  3. unclear risk of bias: plausible bias that raises some doubt about the results.

If the assessors disagree, the final rating will be made by consensus or with involvement of another member of the review group. When inadequate details of randomisation and other characteristics of trials are provided, authors of the studies will be contacted to obtain further information. Non-concurrence in quality assessment will also be reported.

 

Measures of treatment effect

The main outcome result will be reduction of severity of panic and agoraphobia symptoms. Improvement will usually be presented as a change on a panic disorder scale(s) (mean and standard deviation), as dichotomous outcomes (responder or non-responder, remitted or not-remitted) or as both.

 

Binary or dichotomous data

For binary outcomes, we will calculate a standard estimation of the random-effects model risk ratio (RR) and its 95% confidence interval (CI). It has been shown that a random-effects model has good generalisability (Furukawa 2002) and that RR is more intuitive (Boissel 1999) than odds ratio. Furthermore, odds ratios tend to be interpreted as RRs by clinicians (Deeks 2000). This may lead to an overestimation of the impression of the effect (Higgins 2011). For all primary outcomes, we will calculate the number needed to treat for an additional beneficial outcome or the number needed to treat for an additional harmful outcome statistic (NNTB or NNTH) and its 95% CI using Visual Rx (http://www.nntonline.net/), while taking account of the event rate in the control group.

 

Continuous data

1. Summary statistics

It is likely that different studies have used varied panic rating scales; therefore we will use standardised mean differences (SMDs). If all included studies have used the same instrument, we will use mean differences (MDs).

2. Endpoint versus change data

Trials usually report results using endpoint means and standard deviations of scales or using change in mean values from baseline of assessment rating scales. We prefer to use scale endpoint data, which typically cannot have negative values and are easier to interpret from a clinical point of view. If endpoint data are unavailable, we will use the change data in separate analyses. In case we use MDs, we will pool results based on change data and endpoint data in the same analysis.

 

Unit of analysis issues

 

Cross-over trials

Cross-over trials are trials in which all participants receive both the control and the intervention treatment but in a different order. The major problem is a carryover effect from the first phase to the second phase of the study, especially if the condition of interest is unstable (Elbourne 2002). As this is the case with panic disorder, randomised cross-over studies will be eligible, but only data up to the point of first cross-over will be used.

 

Studies with multiple treatment groups

When a study involves more than two treatment arms, especially two appropriate dose groups of the same drug, the different dose arms will be pooled and considered to be one. If the arms involve one placebo arm and two or more arms of antidepressants of different classes, we will compare each arm with placebo separately. In this case, a unit of analysis error can occur because of the unaddressed differences between the estimated intervention effects from multiple comparisons (Higgins 2011), resulting in double counting. To avoid this, we will include each pair-wise comparison separately, according to the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions, Section 16.5.4 (Higgins 2011). If the variable is dichotomous, we will divide the shared interventions group evenly among the comparisons. If the variable is continuous, only the total number of participants will be divided up, and means and standard deviations will be left unchanged.

 

Cluster-randomised trials

In cluster-randomised trials, groups of individuals rather than separate individuals are randomly assigned to different interventions. In case we identify cluster placebo-controlled randomised trials, we plan to use the generic inverse variance technique if such trials have been appropriately analysed, while taking into account intraclass correlation coefficients to adjust for cluster effects. When trialists have not adjusted for the effects of clustering, we will attempt to do this by obtaining an intracluster correlation coefficient and then following the guidance given in Chapter 16.3.4 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).

 

Dealing with missing data

We will try to contact the study authors to obtain all relevant missing data.

1. Dichotomous outcomes

Response, or remission on treatment, will be calculated using an intention-to-treat (ITT) analysis. We will follow the principle 'once randomised always analysed'. When participants left the study before the intended endpoint, it will be assumed that they would have experienced the negative outcome. The validity of the above assumption will be tested by sensitivity analysis, with application of worst and best case scenarios. When dichotomous outcomes are not reported but the baseline mean and standard deviation on a panic disorder scale are reported, we will calculate the number of responding or remitted participants according to a validated imputation method (Furukawa 2005). The validity of the above approach will be analysed by sensitivity analysis. If necessary, authors of studies will be contacted to obtain data and/or clarification.

2. Continuous outcomes

Concerning continuous data, the Cochrane Handbook for Systematic Reviews of Interventions recommends avoiding imputations of continuous data and suggests that data should be used as presented by the original authors. When ITT data are available, they will be preferred to 'per-protocol analysis'. If necessary, authors of studies will be contacted to obtain data and/or clarification.

3. Skewed or qualitative data

Skewed or qualitative data will be presented descriptively.

Several strategies will be considered for skewed data. If papers report a mean and a standard deviation, and an absolute minimum possible value is also available for the outcome, we will divide the mean by the standard deviation. If the value obtained is less than two, we will conclude that some skewness is indicated. If the value obtained is less than one (i.e. the standard deviation is larger than the mean), skewness is almost certain. If papers have not reported the skewness and simply report means, standard deviations and sample sizes, these numbers will be used. Because these data may not have been properly analysed and can be misleading, analyses will be conducted with and without these studies. If the data have been log-transformed for analysis, and geometric means are reported, skewness will be reduced. This is the recommended method of analysis of skewed data (Higgins 2011). If papers use non-parametric tests and describe averages using medians, they cannot be formally pooled in the analysis. We will follow the recommendation made by Cochrane that results of these studies be reported in a table in our review, along with all other papers. This means that the data will not be lost from the review, and the results can be considered when conclusions are drawn, even if they cannot be formally pooled in the analyses.

4. Missing statistics

When only P or standard error (SE) values are reported, we will calculate standard deviations (SDs) (Altman 1996). In the absence of supplementary data after requests have been made to the authors, the SDs will be calculated according to a validated imputation method (Furukawa 2006). We will examine the validity of these imputations in the sensitivity analyses.

 

Assessment of heterogeneity

In accordance with the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions, heterogeneity will be quantified by the I2 statistic. The Cochrane Handbook for Systematic Reviews of Interventions recommends overlapping intervals for I2 interpretation (Section 9.5.2, Higgins 2011) as follows:

  • 0% to 40%: might not be important;
  • 30% to 60%: may represent moderate heterogeneity;
  • 50% to 90%: may represent substantial heterogeneity; and
  • 75% to 100%: may represent considerable heterogeneity.

We will also use the Chi2 test and its P value to determine the direction and magnitude of the treatment effects. In a meta-analysis of few trials, Chi2 will be underpowered to detect heterogeneity, if it exists. P = 0.10 will be used as a threshold of statistical significance.

 

Assessment of reporting biases

Reporting biases arise when dissemination of research findings is influenced by the nature and direction of the results. These are described in Section 10 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). A funnel plot is usually used to investigate publication bias. However, it has a limited role when only a few studies of similar size are identified. Also, asymmetry of a funnel plot does not always reflect publication bias. Visual inspection of funnel plots will be used to assess publication bias, as will a statistical test for funnel plot asymmetry, as proposed by Eggers or Rücker (Higgins 2011). We will not use funnel plots for outcomes if 10 or fewer studies are identified, or if all studies are of similar size.

 

Data synthesis

We will use a random-effects model to calculate treatment effects. We prefer the random-effects model, as it takes into account differences between studies, even when no evidence of statistical heterogeneity is found. It gives a more conservative estimate than the fixed-effect model. We note that the random-effects model gives added weight to the findings of small studies, which can either increase or decrease the effect size. We will apply a fixed-effect model to primary outcomes only to see whether this markedly changes the effect size.

 

Subgroup analysis and investigation of heterogeneity

Subgroup analyses are often exploratory in nature and should be interpreted cautiously, first, because they often involve multiple analyses and lead to false-positive results; and second, because these analyses lack power and are more likely to result in false-positive results. While keeping in mind the above reservations, we would perform the following subgroup analyses.

  1. For participants with agoraphobia and for participants without agoraphobia, we would perform subgroup analyses because the same treatment may have differential effectiveness with regard to panic and agoraphobia.
  2. If groups within any of the subgroups are found to be significantly different from one another, we will run meta-regression for exploratory analyses of additive or multiplicative influences of the variables in question.
  3. We will compare acute phase treatment studies that last less than four months with acute phase treatment studies that last four months or longer.

 

Sensitivity analysis

The following sensitivity analyses will be planned a priori. We will examine whether the results change and will check for the robustness of observed findings by:

  1. excluding trials with high risk of bias (i.e. trials with inadequate allocation concealment and blinding, with incomplete data reporting and/or with high probability of selective reporting);
  2. excluding trials with dropout rates greater than 20%;
  3. excluding studies funded by the pharmaceutical company marketing each azapirone. This sensitivity analysis is particularly important (a) because repeated findings indicate that funding strongly affects outcomes of research studies (Als-Nielsen 2003; Lexchin 2003; Bhandari 2004), and (b) because industry sponsorship and authorship of clinical trial reports have increased over the past 20 years (Buchkowsky 2004); and
  4. excluding studies whose participants clearly have significant psychiatric comorbidities, including primary or secondary depressive disorders.

Our routine application of random-effects and fixed-effect models, as well as our secondary outcomes of remission rates and continuous severity measures, might be considered additional forms of sensitivity analyses.

 

Summary of findings table

We will summarise the findings using a 'Summary of findings' table, according to the GRADE approach (Higgins 2011).

 

Acknowledgements

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Contributions of authors
  7. Declarations of interest
  8. Sources of support
  9. Notes

CRG Funding Acknowledgement
The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane Depression, Anxiety and Neurosis Group. 

Disclaimer
The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, the National Health Service (NHS) or the Department of Health.

 

Contributions of authors

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Contributions of authors
  7. Declarations of interest
  8. Sources of support
  9. Notes

GG devised the idea. GG, CB and AC worked on the first draft of the protocol. MK, SJCD, HI and DC provided suggestions and input. All authors reviewed and approved the final version of the protocol.

 

Declarations of interest

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Contributions of authors
  7. Declarations of interest
  8. Sources of support
  9. Notes

GG, CB, DC, AC, SJCD, HI and MK: none.

 

Sources of support

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Contributions of authors
  7. Declarations of interest
  8. Sources of support
  9. Notes
 

Internal sources

  • None, Not specified.

 

External sources

  • None, Not specified.

 

Notes

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Acknowledgements
  6. Contributions of authors
  7. Declarations of interest
  8. Sources of support
  9. Notes

This protocol is one of several separate reviews examining the efficacy and tolerability of pharmacological and non-pharmacological treatments for panic disorders. These individual reviews will be combined in a multiple-treatment meta-analysis using multiple-treatments model methodology (protocol to be published in The Cochrane Library).

References

Additional references

  1. Top of page
  2. Abstract
  3. Background
  4. Objectives
  5. Methods
  6. Acknowledgements
  7. Contributions of authors
  8. Declarations of interest
  9. Sources of support
  10. Notes
  11. Additional references
Als-Nielsen 2003
  • Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?. Journal of the American Medical Association 2003;290:921-8.
Altman 1996
  • Altman DG, Bland MJ. Detecting skewness for summary information. BMJ 1996;313:1200.
APA 1994
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Arlington, VA: American Psychiatric Publishing, 1994.
APA 2009
  • American Psychiatric Association. American Psychiatric Association Practice Guidelines for the Treatment of Panic Disorder. American Psychiatric Association Practice Guideline for the Treatment of Panic Disorder. Arlington, VA: American Psychiatric Publishing, 2009.
BAP 2005
  • Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association forPsychopharmacology. Journal of Psychopharmacology 2005;19:567-96.
Batelaan 2011
  • Batelaan NM, Van Balkom AJ, Stein DJ. Evidence-based pharmacotherapy of panic disorder: an update. International Journal of Neuropsychopharmacology 2011:1-13. [10.1017/S1461145711000800 [Epub ahead of print]]
Bhandari 2004
  • Bhandari M, Busse JW, Jackowski D, Montori VM, Schünemann H, Sprague S, et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. Canadian Medical Association Journal 2004;170:477-80.
Bijl 1998
  • Bijl RV, Ravelli A, van Zessen G. Prevalence of psychiatric disorder in the general population: results of The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Social Psychiatry and Psychiatric Epidemiology 1998;33:587-95.
Boissel 1999
  • Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. Comparison of the indices and their use. Therapie 1999;54:405-11.
Brooks 2002
  • Broocks A, Meyer T, Opitz M, Bartmann U, Hillmer-Vogel U, George A, et al. 5 -HT1A responsivity in patients with panic disorder before and after treatment with aerobic exercise, clomipramine or placebo. European Neuropsychopharmacology 2003;13:153-64.
Bruce 2003
  • Bruce SE, Vasile RG, Goisman RM, Salzman C, Spencer M, Machan JT, Keller MB. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia?. American Journal of Psychiatry 2003;160:1432-8.
Buchkowsky 2004
Cohen 1960
Deeks 2000
  • Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; Cape Town, South Africa. 2000 October 25-28.
Diaz 2011
  • Diaz MR, Chappell AM, Christian DT, Anderson NJ, McCool BA. Dopamine D3-like receptors modulate anxiety-like behavior and regulate GABAergic transmission in the rat lateral/basolateral amygdala. Neuropsychopharmacology 2011;36:1090-103.
Eaton 1994
Elbourne 2002
  • Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31:140-9.
Furukawa 2002
  • Furukawa TA, Guyatt GH, Griffith LE. Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses. International Journal of Epidemiology 2002;31:72-6.
Furukawa 2005
  • Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N. Imputing response rates from means and standard deviations in meta-analysis. International Clinical Psychopharmacology 2005;20:49-52.
Furukawa 2006
  • Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2000;59:7-10.
Goisman 1995
  • Goisman RM, Warshaw MG, Steketee GS, Fierman EJ, Rogers MP, Goldenberg I, et al. DSM-IV and the disappearance of agoraphobia without a history of panic disorder: new data on a controversial diagnosis. American Journal of Psychiatry 1995;152:1438-43.
Gorman 2000
Grant 2006
  • Grant BF, Hasin DS, Stinson FS, Dawson DA, Goldstein RB, Smith S, et al. The epidemiology of DSM-IV panic disorder and agoraphobia in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry 2006;67:363-74.
Guaiana 2013
  • Guaiana G, Barbui C, Chiodo D, Cipriani A, Davies SJC, Koesters M. Antidepressants versus placebo for panic disorder in adults. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI: 10.1002/14651858.CD010676]
Guaiana 2013a
  • Guaiana G, Barbui C, Chiodo D, Cipriani A, Davies SJC, Koesters M. Benzodiazepines versus placebo for panic disorder in adults. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI: 10.1002/14651858.CD010677]
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley & Sons, 2011.
Kessler 2006
  • Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Archives of General Psychiatry 2006;63:415-24.
King 2008
  • King M, Nazareth I, Levy G, Walker C, Morris R, Weich S, et al. Prevalence of common mental disorders in general practice attendees across Europe. British Journal of Psychiatry 2008;192:362-7.
Kishi 2013
  • Kishi T, Meltzer Y, Iwata N. Augmentation of antipsychotic drug action byazapirone 5-HT1A receptor partial agonists: a meta-analysis. International Journal of Neuropsychopharmacology 2013;16:1259-66.
Klein 1964
Lesch 1992
Lexchin 2003
Moher 2009
Napoliello 1991
Nash 2008
  • Nash JR, Sargent PA, Rabiner EA, Hood SD, Argyropoulos SV, Potokar JP, et al. Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study. British Journal of Psychiatry 2008;193:229-34.
NICE 2011
  • National Institute for Health and Care Excellence. Generalised Anxiety Disorder and Panic Disorder (With or Without Agoraphobia) in Adults [CG113]. London: National Institute for Health and Care Excellence, 2011.
Parks 1998
Payer 2013
  • Payer D, Bolleau I, Guranda M, Graff A, Nakajima S, Meyer J, et al. Buspirone occupancy of D2/3 dopamine receptors in humans measured by positron emission tomography. Proceedings of the College on Problems of Drug Dependence, 75th Annual Scientific Meeting, San Diego, CA. 15-20 June 2013.
Pompoli 2013
  • Pompoli A, Furukawa TA, Imai H, Tajika A, Efthimiou O, Salanti G. Psychological therapies for panic disorder with or without agoraphobia in adults. Cochrane Database of Systematic Reviews (in press).
Starcevic 2009
  • Starcevic V. Anxiety Disorders in Adults: A Clinical Guide. Oxford, UK: Oxford University Press, 2009.
Stein 2010
  • Stein M, Steckler T, Lightfoot JD, Hay E, Goddard AW. Pharmacologic treatment of panic disorder. Current Topics in Behavioral Neurosciences 2010;2:469-85.
Tauscher 2001
  • Tauscher J, Bagby RM, Javanmard M, Christensen BK, Kasper S, Kapur S. Inverse relationship between serotonin 5-HT(1A) receptor binding and anxiety: a [(11)C]WAY-100635 PET investigation in healthy volunteers. Am J Psychiatry 2001;158:1326-8.
Wade 1999
  • Wade AG. Antidepressants in panic disorder. International Clinical Psychopharmacology 1999;14(Suppl 2):13-7.
Watanabe 2009